<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04942080</url>
  </required_header>
  <id_info>
    <org_study_id>49RC21_0156</org_study_id>
    <nct_id>NCT04942080</nct_id>
  </id_info>
  <brief_title>Interest of CALR Allele Burden in Diagnosis and Follow-up of Patients With CALR Mutated Myeloproliferative Syndromes (CALRSUIVI)</brief_title>
  <acronym>CALRSUIVI</acronym>
  <official_title>Interest of CALR Allele Burden in Diagnosis and Follow-up of Patients With CALR Mutated Myeloproliferative Syndromes (CALRSUIVI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Angers</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ligue contre le cancer, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Angers</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective study to evaluate the relevance of CALR allele burden monitoring as a molecular&#xD;
      marker of disease progression.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A first local study on 45 patients showed the prognostic impact of CALR mutation&#xD;
      quantification in follow-up, independently of the European LeukemiaNet (ELN) prognostic score&#xD;
      validated in this group of patients.&#xD;
&#xD;
      This study aims to evaluate a multicenter cohort of 260 patients, including all types of&#xD;
      CALR-mutated MPNs and several follow-up samples, to model the temporal evolution of CALR&#xD;
      allele burden.&#xD;
&#xD;
      Blood of MPN patients will be collected, at the time of diagnosis and for 3 years (max 1&#xD;
      sample/year), for the quantification of the CALR allele burden. During follow-up, a&#xD;
      clinicobiological score to define the progression or not of the disease for each patient will&#xD;
      be evaluated in Essential Thrombocythemia (ET) and MyeloFibrosis (MF).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>For each disease, Hazard Ratio of the different trajectories of CALR allele burden to explain the time to onset of disease progression by the clinicobiological score.</measure>
    <time_frame>3 years follow-up</time_frame>
    <description>Clinicobiological score :&#xD;
For ET, disease progression if ≥ 1 of:&#xD;
leukocytosis &gt; 12 G/L or myelemia &gt; 10% or erythroblasts &gt; 1%,&#xD;
anemia or thrombocytopenia not related to drug toxicity,&#xD;
development or worsening of splenomegaly,&#xD;
development of thrombocytosis (platelets &gt; 450 G/L) on cytoreductive therapy,&#xD;
poor disease control (at least one change in therapy for reasons other than adverse events),&#xD;
hematologic transformation or death related to hematologic pathology.&#xD;
For MF, disease progression if ≥ 1 of:&#xD;
anemia &lt; 100 g/L, neutropenia &lt; 1 G/L, thrombocytopenia &lt; 100 G/L and/or development of general signs not previously present or recurring after improvement,&#xD;
increase in leukocytosis &gt; 25 G/L not previously present,&#xD;
appearance or aggravation of transfusion dependence,&#xD;
appearance (&gt; 5 cm) or aggravation (&gt; 50%) of splenomegaly,&#xD;
leukemic transformation or death related to the hematologic pathology.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>A multinomial logistic model will be performed to identify the characteristics associated with the different trajectories of CALR allele burden (pathology, treatment, additional mutations, type of CALR mutation).</measure>
    <time_frame>3 years follow-up</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Myeloproliferative Neoplasm</condition>
  <condition>Essential Thrombocythemia</condition>
  <condition>Primary Myelofibrosis, Prefibrotic Stage</condition>
  <condition>Primary Myelofibrosis, Fibrotic Stage</condition>
  <arm_group>
    <arm_group_label>CALRSUIVI cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CALR allele burden quantification</intervention_name>
    <description>DNA extraction from blood sample for CALR mutation quantification (fragment analysis)&#xD;
at diagnosis and follow-up (inclusion period: 3 years)&#xD;
max 1 sample/year&#xD;
secondary outcome: mutational landscape by Next Generation Sequencing (NGS) analysis at diagnosis</description>
    <arm_group_label>CALRSUIVI cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  adults (age ≥18 years),&#xD;
&#xD;
          -  affiliated to the national social security system,&#xD;
&#xD;
          -  with CALR mutated myeloproliferative neoplasm diagnosed between 2006 - 2020,&#xD;
&#xD;
          -  for which at least one sample is available at the time of diagnosis or before&#xD;
             cytoreductive treatment,&#xD;
&#xD;
          -  who signed the consent to participate in the study,&#xD;
&#xD;
          -  included, or consenting to be included, in the national clinical-biological database&#xD;
             of France Intergroupe Syndrome Myéloprolifératifs (FIM).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patient with another active hematological disease or cancer at the time of diagnosis,&#xD;
&#xD;
          -  person subject to legal protection scheme or incapable of giving consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Laurane COTTIN, Doctor</last_name>
    <phone>+33 2 41 35 53 53</phone>
    <email>Laurane.Cottin@chu-angers.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emma BLANCHET</last_name>
    <phone>+33 2 41 35 63 38</phone>
    <email>EmBlanchet@chu-angers.fr</email>
  </overall_contact_backup>
  <reference>
    <citation>Cottin L, Riou J, Orvain C, Ianotto JC, Boyer F, Renard M, Truchan-Graczyk M, Murati A, Jouanneau-Courville R, Allangba O, Mansier O, Burroni B, Rousselet MC, Quintin-Roué I, Martin A, Sadot-Lebouvier S, Delneste Y, Chrétien JM, Hunault-Berger M, Blanchet O, Lippert E, Ugo V, Luque Paz D. Sequential mutational evaluation of CALR -mutated myeloproliferative neoplasms with thrombocytosis reveals an association between CALR allele burden evolution and disease progression. Br J Haematol. 2020 Mar;188(6):935-944. doi: 10.1111/bjh.16276. Epub 2019 Nov 11.</citation>
    <PMID>31710700</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 9, 2021</study_first_submitted>
  <study_first_submitted_qc>June 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2021</study_first_posted>
  <last_update_submitted>June 18, 2021</last_update_submitted>
  <last_update_submitted_qc>June 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CALR</keyword>
  <keyword>Myeloproliferative Neoplasm</keyword>
  <keyword>Essential Thrombocythemia</keyword>
  <keyword>Primary Myelofibrosis</keyword>
  <keyword>Thrombocytosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Primary Myelofibrosis</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Thrombocytosis</mesh_term>
    <mesh_term>Thrombocythemia, Essential</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

